Revenue
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V. (PHAR)
Price$10.81Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376.1M | $297.2M | $245.3M | $205.6M | $198.9M | $212.2M | $189.4M | — |
| Gross profit | $330.6M | $261.8M | $220.1M | $188.1M | $177.7M | $188.6M | $165.5M | — |
| Gross margin | 87.90% | 88.09% | 89.72% | 91.46% | 89.37% | 88.91% | 87.37% | — |
| Research & development | $100.4M | $83.1M | $68.9M | $52.5M | $70.4M | $38.5M | $31.8M | — |
| Operating expenses | $304.8M | $270.4M | $225.5M | $169.8M | $164.2M | $112.4M | $97.2M | — |
| Operating income | $25.8M | −$8.6M | −$5.4M | $18.2M | $13.6M | $76.3M | $68.2M | — |
| Operating margin | 6.87% | −2.90% | −2.20% | 8.87% | 6.82% | 35.94% | 36.03% | — |
| EBITDA | $33.8M | −$848,000 | $2.0M | $24.1M | $20.0M | $82.3M | $73.2M | — |
| EBITDA margin | 8.98% | −0.29% | 0.81% | 11.74% | 10.03% | 38.79% | 38.67% | — |
| Net income | $2.5M | −$11.8M | −$10.5M | $13.7M | $16.0M | $37.7M | $40.6M | — |
| Net profit margin | 0.67% | −3.98% | −4.30% | 6.65% | 8.04% | 17.79% | 21.41% | — |
| Basic EPSper basic share | $0.00 | -$0.02 | -$0.02 | $0.02 | $0.03 | $0.06 | $0.07 | — |
| Diluted EPSper diluted share | $0.00 | -$0.02 | -$0.02 | $0.02 | $0.02 | $0.06 | $0.06 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
MAC Alpha Capital Management, LP | 2.15M |
Silverberg Bernstein Capital Management LLC | 41.55K |
Crossmark Global Holdings, Inc. | 12.46K |
CITADEL ADVISORS LLC | 11.97K |
MORGAN STANLEY | 11.5K |
SmartHarvest Portfolios, LLC | 10.42K |
Knoll Capital Management, LLC | 4.09K |
Silver Grove Financial Group, Inc. | 1.07K |
Nalls Sherbakoff Group, LLC | 870 |
Global Retirement Partners, LLC | 456 |
Integrated Wealth Concepts LLC | 380 |
Optiver Holding B.V. | 305 |
BNP PARIBAS FINANCIAL MARKETS | 300 |
NewEdge Advisors, LLC | 187 |
UBS Group AG | 39 |
OSAIC HOLDINGS, INC. | 16 |
Larson Financial Group LLC | 7 |
Caitong International Asset Management Co., Ltd | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
